⌘K
t
| Date | 27 Aug 2024 |
| Time | 07:00:13 |
| Category | Capital structure |
| ID | 6445B |
27 August 2024
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Block Listing Interim Review
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:
|
Name of Company |
Aptamer Group plc |
|
Name of Scheme |
The Aptamer Group EMI Share Option Scheme |
|
Period of Return (from/to) |
25 February 2024 to 24 August 2024 |
|
Number and class of securities not issued at the start of the period under the scheme |
1,666,477 Ordinary Shares |
|
Number of securities issued under the scheme during the period |
0 |
|
Balance under the scheme of securities not yet issued at the end of the period |
1,666,477 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission |
2,063,200 Ordinary Shares on 25 February 2022 |
|
Name of contact and telephone number |
Andrew Rapson +44 (0) 1904 217 404 |
- ENDS -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
About Aptamer Group plc
Aptamer develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.